A GLP-1 journey encompasses the complete treatment experience with glucagon-like peptide-1 receptor agonistsmedications FDA-approved for type 2 diabetes and chronic weight management
Risks were lower with the GLP-1 receptor agonist for major adverse cardiac events (HR 0.66, 95% CI 0.480.91), venous thromboembolism (HR 0.49), kidney disease progression (HR 0.77) and all-cause mortality (HR 0.26)
At present, Spectroscopy (a type of MRI scan) can provide utility in some situations, but ongoing studies of brain structure and chemicals reflect the late pathophysiology of FA and thus are unlikely to be early markers of disease or early effects of treatment
Dimitriu recommends against taking St
Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin
Cardiovascular Protection: Significant data now shows it reduces the risk of heart disease